| Literature DB >> 34071230 |
Masanori Oshi1,2, Vijayashree Murthy1, Hideo Takahashi3, Michelle Huyser1, Maiko Okano4, Yoshihisa Tokumaru1,5, Omar M Rashid6,7, Ryusei Matsuyama2, Itaru Endo2, Kazuaki Takabe1,2,3,8,9,10.
Abstract
Tissue biopsy is the gold standard for diagnosis and morphological and immunohistochemical analyses to characterize cancer. However, tissue biopsy usually requires an invasive procedure, and it can be challenging depending on the condition of the patient and the location of the tumor. Even liquid biopsy analysis of body fluids such as blood, saliva, gastric juice, sweat, tears and cerebrospinal fluid may require invasive procedures to obtain samples. Liquid biopsy can be applied to circulating tumor cells (CTCs) or nucleic acids (NAs) in blood. Recently, urine has gained popularity due to its less invasive sampling, ability to easily repeat samples, and ability to follow tumor evolution in real-time, making it a powerful tool for diagnosis and treatment monitoring in cancer patients. With the development and advancements in extraction methods of urinary substances, urinary NAs have been found to be closely related to carcinogenesis, metastasis, and therapeutic response, not only in urological cancers but also in non-urological cancers. This review mainly highlights the components of urine liquid biopsy and their utility and limitations in oncology, especially in non-urological cancers.Entities:
Keywords: DNA; liquid biopsy; mRNA; microRNA; sncRNA; urine; urine liquid biopsy
Year: 2021 PMID: 34071230 DOI: 10.3390/cancers13112652
Source DB: PubMed Journal: Cancers (Basel) ISSN: 2072-6694 Impact factor: 6.639